NRIX·Nasdaq·US
Nurix
Nurix is a biotechnology company focused on targeted protein degradation for drug discovery and development. It generates revenue through partnerships and collaborations with large pharmaceutical companies, including Sanofi, alongside its own therapeutic pipeline.
Recent Activity
Updated Oct 17, 2026
–Nurix dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL.
–Nurix enrolled the first patient in a Phase 1b/2 cohort combining bexobrutideg with venetoclax in chronic lymphocytic leukemia, with the initial cohort focused on relapsed/refractory CLL and potential expansion to first-line.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.